A Randomized, Double-Blind, Placebo-Controlled, Single Dose, Oral, Dose Escalation Phase 1 Study to Evaluate the Safety and Tolerance of MF 101 as Well as the Pharmacokinetics of Its Key Active Components in Healthy Post-Menopausal Women.
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2009
At a glance
- Drugs MF 101 (Primary)
- Indications Vasomotor symptoms
- Focus Adverse reactions
- 15 Dec 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 07 Jun 2007 New trial record.